Managers / Q1 2023 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $241M in U.S.-listed holdings across 12 positions for Q1 2023.
Its largest position, Blueprint Medicines, represents 11.6% of the portfolio.
Compared with Q4 2022, the fund opened 1 new position and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 50.5% · $122M
- ETP · 29.3% · $71M
- ADR · 10.9% · $26M
- Other · 9.3% · $23M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| QQQINVESCO QQQ TR | NEW | +220.0K | 220.0K | +$71M | $71M |
| XBIS&P BIOTECH ETF TR | SOLD OUT | −500.0K | 0 | −$42M | $0 |
| AMRYT PHARMA PLC | SOLD OUT | −2.10M | 0 | −$15M | $0 |
| MERUS N V | TRIMMED | −207.0K | 1.23M | +$387,280 | $23M |
| ARWRARROWHEAD PHARMACEUTICALS IN | TRIMMED | −85.0K | 1.02M | −$19M | $26M |
| RGNXREGENXBIO INC | TRIMMED | −66.7K | 831.0K | −$5M | $16M |
| BLUEPRINT MEDICINES CORP | ADDED | +41.1K | 622.8K | +$3M | $28M |
| ARVNARVINAS INC | TRIMMED | −45.0K | 628.9K | −$6M | $17M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BLUEPRINT MEDICINES CORP | COM | 11.61% | $28M | 622.8K |
| 2 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 10.72% | $26M | 1.02M |
| 3 | MERUS N V | COM | 9.34% | $23M | 1.23M |
| 4 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 7.38% | $18M | 601.3K |
| 5 | ARVNARVINAS INChistory → | COM | 7.12% | $17M | 628.9K |
| 6 | RGNXREGENXBIO INChistory → | COM | 6.51% | $16M | 831.0K |
| 7 | QUREUNIQURE NVhistory → | SHS | 5.32% | $13M | 637.5K |
| 8 | GMABGENMAB A/Shistory → | SPONSORED ADS | 3.80% | $9M | 242.8K |
| 9 | ARGXARGENX SEhistory → | SPONSORED ADR | 3.71% | $9M | 24.0K |
| 10 | SLNSILENCE THERAPEUTICS PLChistory → | ADS | 3.37% | $8M | 1.31M |
| 11 | PIERIS PHARMACEUTICALS INC | COM | 1.84% | $4M | 4.55M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.